Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.37 USD
Change Today -0.04 / -0.62%
Volume 4.9K
HSGX On Other Exchanges
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

histogenics corp (HSGX) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/3/14 - $12.97
52 Week Low
06/30/15 - $6.01
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for HISTOGENICS CORP (HSGX)

Related News

No related news articles were found.

histogenics corp (HSGX) Related Businessweek News

No Related Businessweek News Found

histogenics corp (HSGX) Details

Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace. Its product candidate includes NeoCart, which is in Phase III clinical trials, a first-line therapy for full thickness knee chondral lesions in skeletally mature adults age 18 to 55. The company has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.

42 Employees
Last Reported Date: 03/27/15
Founded in 2000

histogenics corp (HSGX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $224.3K
Senior Vice President of Technical Operations
Total Annual Compensation: $309.2K
Compensation as of Fiscal Year 2014.

histogenics corp (HSGX) Key Developments

Histogenics Corporation Appoints Jonathan Lieber as Chief Financial Officer, Effective July 2, 2015

Histogenics Corporation announced the appointment of Jonathan Lieber as its Chief Financial Officer, effective July 2, 2015. Mr. Lieber has more than 20 years of executive management experience at emerging growth life sciences companies and in investment banking. He brings a track record of success, leading both development-stage and commercial companies throughout his career, and will oversee all financial, business development, investor relations and administrative functions at the company. Prior to the company, Mr. Lieber most recently served as the CFO of Metamark Genetics Inc., as the CFO and Treasurer of Repligen Corporation, and the CFO of Xcellerex Inc. (acquired by GE Healthcare).

Histogenics Corporation Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Histogenics Corporation announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, loss from operations was $7,873,000 compared to $5,173,000 a year ago. Loss attributable to common stockholders - basic and diluted was $7,964,000 or $0.60 basic and diluted per share compared to $3,437,000 or $5.90 basic and diluted per share a year ago.

Histogenics Corporation Announces Scientific Advisory Board Appointments

Histogenics Corporation announced the creation of its new Scientific Advisory Board comprised of internationally renowned scientists and researchers. The SAB's mission will be to provide strategic scientific and technical oversight as Histogenics brings NeoCart, Histogenics' lead product candidate, through its Phase 3 clinical trial, leverages its recent biomaterials manufacturing experience, and advances its product pipeline which may include next-generation therapies and additional indications of NeoCart. Histogenics Scientific Advisory Board is comprised of Dr. Kyriacos A. Athanasiou: Distinguished Professor of Biomedical Engineering and Orthopedic Surgery, the Child Family Professor of Engineering, and the immediate past Chair of Biomedical Engineering at the University of California Davis. He has served as president of the Biomedical Engineering Society. Additionally, he is the Editor-in-Chief of the Annals of Biomedical Engineering. Dr. Charles L. Cooney: Robert T. Haslam Professor of Chemical Engineering, Emeritus; MIT Department of Chemical Engineering. Dr. Jennifer Elisseeff: Jules Stein Professor; Wilmer Eye Institute and Biomedical Engineering, and Director; Translational Tissue Engineering Center, Johns Hopkins University. Dr. Shuichi Mizuno: Assistant Professor, Orthopedic Surgery; Harvard Medical School. Co-founder of Histogenics Corporation. Dr. Lonnie Shea: Professor and Chair; Biomedical Engineering, University of Michigan. He joined the faculty at the University of Michigan in 2014 bringing his active research group working at the interface of tissue engineering, gene therapy, and drug delivery. Dr. R. Lane Smith: Professor of Orthopedic Surgery; Stanford University School of Medicine. His research focuses on the mechanisms of cartilage degradation in inflammation and sepsis and the stimulation of cartilage growth and repair by growth factors and hormones in serum-free culture. His research also focuses on the effects of adherence and deposition of glycocalyx on bacterial resistance to antibiotic treatment.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HSGX:US $6.37 USD -0.04

HSGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HSGX.
View Industry Companies

Industry Analysis


Industry Average

Valuation HSGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HISTOGENICS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at